Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ETON with free AI briefings, catalyst countdowns, and dilution alerts.

ETON · Eton Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$55.6M Cash on Hand
CF+ Cash Runway
Follow ETON by email Get an email when ETON reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ETON, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-03-29 VALTOCO (Aquestive) seizure rescue in ages 6 to 11 NDA 66% ±43% by May 21
2027-05-28 KHINDIVI NDA 66% –

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ETON Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

ETON holds $55.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ETON files for a raise →

👥 Who Owns ETON

Insiders 13.8% Institutions (287 holders) 74.9% Public and other holders 11.3%
HolderTypeShares% of sharesAs of
EcoR1 Capital, LLC Institution (13G, 5%+) 2,470,920 8.57% 2026-09-30
Opaleye Management Inc.
10% owner
Insider 2,440,000 8.46% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 1,882,410 6.53% 2026-06-30
Sean Brynjelsen
President & CEO, Director · +6.32M options
Insider 961,194 3.33% 2026-08-19
Norbert G Riedel
Director · +590,749 options
Insider 224,300 0.78% 2026-04-21
James R. Gruber
Chief Financial Officer · +534,006 options
Insider 213,420 0.74% 2026-01-12
Paul V Maier
Director · +590,749 options
Insider 72,245 0.25% 2026-08-28
David Krempa
Chief Business Officer · +1.11M options
Insider 43,381 0.15% 2026-10-06
Danka Radosavljevic
Chief Operating Officer
Insider 22,473 0.08% 2026-07-31
Ipek Erdogan-Trinkaus
Chief Commercial Officer · +390,767 options
Insider 4,081 0.01% 2026-11-10

Share count 28,842,215 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-02-25 DESMODA NDA +22% -3.5% -4.5%

Browse all historical PDUFA outcomes →

Get the full ETON picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ETON and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.